Article History
Received: 6 January 2026
Accepted: 9 March 2026
First Online: 19 March 2026
Declarations
:
: DEL received research support from BTG International, Metro International Biotech LLC, Renibus Therapeutics, Inc., Alexion Pharmaceuticals, and 60 Degrees Pharmaceuticals, Inc., and served as a consultant for Entrada Therapeutics, CardioRenal Systems, Inc., and Alexion Pharmaceuticals. SG and BG declare no competing interest regarding the submitted work. The authors declare no funding source regarding the submitted work.
: An ethics approval was not applicable, as no new patients were included.